Weber Appointed President of CooperVision
Commenting on the appointment, Robert S. Weiss, Cooper's chief executive officer, said, "John brings extensive worldwide operational experience to his new role. With his background and experience within CooperVision, he is ideally suited to continue driving our success."
TVCI Satellite Learning Center Opens at SCCO
"The satellite learning centers provide a direct link between the main campus of The Vision Care Institute in Jacksonville, Florida, and the optometry schools, enhancing students' experiences with even more information and skills useful for their careers," says Richard Clompus, O.D., FAAO, Director, The Vision Care Institute, LLC. "Educational programming at the satellite centers includes distance learning programs for first- through fourth-year optometry students, using video conferencing technologies from the Jacksonville headquarters. Additional satellite centers will be built at other optometry schools in the future."
"The Vision Care Institute Satellite Learning Center at the Southern California College of Optometry is the key link in completing the state-of-the-art campus," said Dr. Lesley Walls, President of SCCO. "I anticipate a high demand for its use by our faculty and students and anticipate that it will help promote professional private practice for our graduates."
Increased Comfort Delivers Lasting Patient Satisfaction
More About ACUVUE® OASYS™
Important Safety Information
--ADVERTISING
Marietta Vision Introduces VisionCare 2 Contact Lens
Blanchard Contact Lens Presents Donation to National Keratoconus Foundation
"As manufacturer of the Rose K family of lens products in North America, and in recognition and support of keratoconus contact lens practitioners fitting Rose K lenses, we feel an obligation to provide continued support for the dedication and efforts the National Keratoconus Foundation provides these patients", said Lee Buffalo, Director of Sales and Marketing at Blanchard.
Alimera Sciences Signs Second Agreement with Emory University for Potential Treatments Using New Class of Antioxidants
According to Alimera, the agreement gives the company the exclusive option to license a class of small molecule compounds, known as triphenylmethanes, as a potential treatment for ocular disorders such as diabetic retinopathy and the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition, which is known as geographic atrophy. This agreement is in addition to the September 2007 option to license the NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors for similar treatments.
"This second agreement with Emory expands our opportunity to develop expertise in the management of ROS and its damaging effects on the eye," said Dan Myers, President and CEO for Alimera Sciences. "Researching these compounds, as well as the NADPH oxidase inhibitor compounds from our previous agreement with Emory, provides Alimera with an excellent chance of addressing these significant ophthalmic disorders."
Per the company announcement, Alimera will be responsible for both the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.
Abstract: Topiramate for the Treatment of Chronic Corneal Pain
N.M. is a 28-year-old woman with posttraumatic recurrent corneal erosions treated with bandage contact lenses, Muro-128, topical ketorolac, doxycycline, stromal micropuncture, and laser epithelial keratomileusis over the course of four years. Because of persistent episodes of corneal pain, she was prescribed topiramate.
Before starting topiramate therapy, N.M. had experienced 3-4 awakenings at night because of pain and 5-6 episodes of spontaneous tearing and pain during the day. She started topiramate at 25 mg orally four times a day without significant change in her symptoms. After one week, the dose was escalated to 50 mg orally four times a day, and within one day, she experienced 0-1 awakenings at night. She had approximately 2-3 episodes of pain and tearing during the day. The dose was escalated to 100 mg orally four times a day. At that dose, the patient continued to have pain relief but complained of nausea. The patient's topiramate was weaned off to determine whether her symptom relief was caused by the medication or improvement in her condition. Once off the topiramate, N.M.'s nausea resolved but her corneal symptoms returned at the same frequency as before the initiation of topiramate. Therefore, she was restarted on topiramate 50 mg orally four times a day with rapid onset of improvement in her symptoms.
The authors concluded that anticonvulsants such as topiramate may be effective in the management of pain caused by recurrent corneal erosions.
Nampiaparampil DE, Nampiaparampil RG, Prasad AG. Topiramate for the treatment of chronic corneal pain.
Cornea. 2008 Jan;27(1):124-6.
Editor's Commentary: The Business of Eye Care
Carla Mack, O.D., F.A.A.O.